title: Association between beta cell function and future glycemic control in patients with type 2 diabetes.
abstract: The aim of this study was to clarify the association between C-peptide immunoreactivity (CPR), a marker of beta cell function, and future glycemic control in patients with type 2 diabetes. We conducted a retrospective analysis of 513 consecutive patients with type 2 diabetes who were admitted to our hospital between 2000 and 2007 and followed up for 2 years. Serum and urinary CPR levels were measured during admission, and CPR index was calculated as the ratio of CPR to plasma glucose. The associations between these markers at baseline and glycemic control after 2 years were assessed by means of logistic regression models. After 2 years, 167 patients (32.6%) showed good glycemic control (HbA1c <6.9%). Baseline serum and urinary CPR indices were significantly associated with good glycemic control after 2 years, and the postprandial CPR to plasma glucose ratio (postprandial CPR index) showed the strongest association (odds ratio (OR) 1.29, 95% confidence interval (CI) 1.12-1.50, P = 0.001) among CPR indices. Multivariate analyses showed consistent results (OR 1.23, 95%CI 1.03-1.48, P = 0.021). In conclusion, preserved beta cell function at baseline was associated with better glycemic control thereafter in patients with type 2 diabetes.
authors.affiliation: Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan. ysaisho@z5.keio.jp
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Saisho
authors.forename: Kinsei
authors.initials: K
authors.lastname: Kou
authors.forename: Kumiko
authors.initials: K
authors.lastname: Tanaka
authors.forename: Takayuki
authors.initials: T
authors.lastname: Abe
authors.forename: Akira
authors.initials: A
authors.lastname: Shimada
authors.forename: Toshihide
authors.initials: T
authors.lastname: Kawai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Itoh
mesh_terms: D000368:Aged; D000465:Algorithms; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control*; D007003:Hypoglycemia / Q000517:prevention & control*; D050417:Insulin-Secreting Cells / Q000378:metabolism*; D016015:Logistic Models; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D019518:Postprandial Period; D012189:Retrospective Studies
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D002096:C-Peptide; D006442:Glycated Hemoglobin; C517652:hemoglobin A1c protein, human